About the bill
- Full Title
A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes.
The bill’s title was written by its sponsor.
Read CRS Summary >
Jun 26, 2007
This is the first step in the legislative process.
Read Text »
Jun 27, 2007
Reported by Committee
A committee has issued a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.
Read Text »
See Changes »
This is a Senate bill in the United States Congress (indicated by the “S.” in “S. 1695”). A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
4 cosponsors (2R, 2D)
- Committee Assignments
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 1695 — 110th Congress: Biologics Price Competition and Innovation Act of 2007. Retrieved from https://www.govtrack.us/congress/bills/110/s1695
“S. 1695 — 110th Congress: Biologics Price Competition and Innovation Act of 2007.” www.GovTrack.us. 2007. February 14, 2016 <https://www.govtrack.us/congress/bills/110/s1695>
|title=S. 1695 (110th)
|accessdate=February 14, 2016
|author=110th Congress (2007)
|date=June 26, 2007
|quote=Biologics Price Competition and Innovation Act of 2007